Surprise as Amgen pips Regeneron/Sanofi to first PCSK9 inhibitor approval
This article was originally published in Scrip
Executive Summary
While all eyes were on the US market, Amgen has clinched victory over Regeneron/Sanofi in the race to be first to approval with a PCSK9 inhibitor in another major territory, the EU.